291 related articles for article (PubMed ID: 22272895)
1. Antiplatelet therapy in patients with diabetes mellitus.
Grove EL; Gregersen S
Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
Coccheri S
Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove EL
Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
[TBL] [Abstract][Full Text] [Related]
4. Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
Capranzano P; Capodanno D
Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):307-17. PubMed ID: 23469911
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of the antiplatelet effect of aspirin.
Würtz M; Kristensen SD; Hvas AM; Grove EL
Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
[TBL] [Abstract][Full Text] [Related]
6. Novel antiplatelet agents in acute coronary syndrome.
Franchi F; Angiolillo DJ
Nat Rev Cardiol; 2015 Jan; 12(1):30-47. PubMed ID: 25286881
[TBL] [Abstract][Full Text] [Related]
7. Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Ferreiro JL; Angiolillo DJ
Curr Pharm Des; 2012; 18(33):5273-93. PubMed ID: 22724415
[TBL] [Abstract][Full Text] [Related]
8. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
Natarajan A; Zaman AG; Marshall SM
Diab Vasc Dis Res; 2008 Jun; 5(2):138-44. PubMed ID: 18537103
[TBL] [Abstract][Full Text] [Related]
9. [Antiplatelet agents].
Steg G
Bull Acad Natl Med; 2013 Feb; 197(2):375-87; discussion 387-8. PubMed ID: 24919367
[TBL] [Abstract][Full Text] [Related]
10. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
[TBL] [Abstract][Full Text] [Related]
11. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Liu L; Li J; Zhang Y; Zhang S; Ye J; Wen Z; Ding J; Kunapuli SP; Luo X; Ding Z
Thromb Res; 2014 Oct; 134(4):866-76. PubMed ID: 25077998
[TBL] [Abstract][Full Text] [Related]
12. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Valentine N; Van de Laar FA; van Driel ML
Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
[TBL] [Abstract][Full Text] [Related]
13. Oral Antiplatelet Therapy in Coronary Disease.
Falcão Gonçalves P; Menezes Falcão L
Am J Ther; 2017; 24(6):e744-e750. PubMed ID: 26752652
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
15. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet drugs. A comparative review.
Schrör K
Drugs; 1995 Jul; 50(1):7-28. PubMed ID: 7588091
[TBL] [Abstract][Full Text] [Related]
17. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
18. New perspectives in antiplatelet therapy.
Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
[TBL] [Abstract][Full Text] [Related]
19. Update on oral antiplatelet therapy: principles, problems and promises.
Grove EL; Kristensen SD
Future Cardiol; 2009 May; 5(3):247-58. PubMed ID: 19450051
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
